Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 13;102(41):e35495.
doi: 10.1097/MD.0000000000035495.

Causal relationship between chronic obstructive pulmonary disease and BMD at different sites: A bidirectional Mendelian randomization study

Rui Jiang  1   2 , Shuanglin Mou  2 , Feng Luo  3 , Zheng Zhang  2   4
Affiliations

Causal relationship between chronic obstructive pulmonary disease and BMD at different sites: A bidirectional Mendelian randomization study

Rui Jiang et al. Medicine (Baltimore). .

Abstract

Observational studies have demonstrated a correlation between chronic obstructive pulmonary disease (COPD) and osteoporosis (OP). However, it is unclear whether there is genetic causality between COPD and bone mineral density (BMD) reduction at different sites. This study assessed the causal relationship between COPD and BMD in various anatomical locations. Data associated with COPD and BMD were obtained from published genome-wide association studies (GWAS). We selected single nucleotide polymorphisms (SNPs) that were strongly associated with COPD and BMD could serve as instrumental variables for the analysis. Inverse variance weighted, MR-Egger and weighted median were manipulated to evaluate causality. Subsequently, we conducted heterogeneity tests using Cochran Q test and tested for pleiotropy using the MR-Egger intercept. We performed leave-one-out sensitivity analysis to assess the robustness of the results. Additionally, we obtained more accurate causal genetic associations by removing any pleiotropic outlying SNPs and performed Mendelian randomization (MR) analysis with the remaining data. Our findings established that COPD was negatively associated with Heel-BMD (odds ratio[OR] = 0.978, 95% confidence interval [CI] = 0.966, 0.990, P = .0003) but not LS-BMD (OR = 0.981, 95% CI: 0.943, 1.020, P = .335), FA-BMD (OR = 0.984, 95% CI: 0.927, 1.046, P = .616), and FN-BMD (OR = 0.981, 95% CI: 0.950, 1.014, P = .249). In reverse MR analysis, the results showed no significant causal effect of BMD at different sites on COPD. The results were proved to be dependable and steady by sensitivity, heterogeneity, and pleiotropy analysis. We found that COPD increases the risk of decreased heel BMD, however, there is no evidence that the loss of BMD increases the risk of COPD.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Schematic representation of the MR study. MR = Mendelian randomization.
Figure 2.
Figure 2.
Forest plots of Mendelian randomization analyses of the causal effects of COPD on BMD at various anatomical locations. BMD = bone mineral density, COPD = chronic obstructive pulmonary disease.
Figure 3.
Figure 3.
Scatter plots and Leave-one-out plot of Mendelian randomization analyses of the causal effects of COPD on BMD at various anatomical locations. A Scatter plots; B Leave-one-out plot. BMD = bone mineral density, COPD = chronic obstructive pulmonary disease.
Figure 4.
Figure 4.
Forest plots of Mendelian randomization analyses of the causal effects of BMD at various anatomical locations on COPD. BMD = bone mineral density, COPD = chronic obstructive pulmonary disease.
Figure 5.
Figure 5.
Scatter plots and Leave-one-out plot of Mendelian randomization analyses of the causal effects of BMD at various anatomical locations on COPD. A Scatter plots; B Leave-one-out plot. BMD = bone mineral density, COPD = chronic obstructive pulmonary disease.
See this image and copyright information in PMC

References

    1. Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet (London, England). 2022;399:2227–42. - PubMed
    1. Kahnert K, Jörres RA, Behr J, et al. The diagnosis and treatment of COPD and its comorbidities. 2023. (Forthcoming):arztebl. m2023. 2027-arztebl. m2023. 2027. - PMC - PubMed
    1. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet (London, England). 2018;391:1706–17. - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 REPORT). Available at: https://goldcopd.org/2023-gold-report-2/.
    1. Zhenlin Z; Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and treatment of primary osteoporosis. Chin Gen Pract. 2023;26:1671–91.

MeSH terms